We are committed to improving population health

We are committed to improving population health

Our Mission, Vision and Strategy

Our Mission is to improve population health by inventing and developing innovative therapies and vaccines, through broad in-house capabilities and creative collaborations, to help address important unmet needs.

Our Vision is to be a leader in providing novel drug therapies and vaccines to improve population health around the world. 

Our Strategy is to use our integrated development engine to advance innovative programs across multiple therapeutic areas into the clinic while maximizing asset potential.

To learn more About Us, view our video.

About Tonix Pharmaceuticals

Tonix has a robust pipeline of programs in development stages ranging from preclinical to mid-Phase 3, across multiple therapeutic modalities, employing varied routes of administration. Tonix’s pipeline is managed by a team of passionate professionals that are adept at advancing innovative programs into the clinic.

While many of Tonix’s product candidates are proprietary, in-house developments, it also has collaborations with world-class academic and non-profit research organizations as well as license agreements with other biotech companies.

Therapeutic Areas

Central Nervous System

Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.

Immunology

We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*

Infectious Disease

Tonix’s infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines, antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to combat infections like SARS-CoV-2.

Rare Disease

Tonix is committed to improving patient care, including for those suffering from rare diseases and for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.

Central Nervous System

Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.

Immunology

We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*

Infectious Disease

Tonix’s infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines, antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to combat infections like SARS-CoV-2.

Rare Disease

Tonix is committed to improving patient care, including for those suffering from rare diseases and for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.

Pipeline Highlights

Using our integrated clinical development engine, we advance innovative programs into the clinic while maximizing asset potential.

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling

Mid-Phase III

TNX-1300   Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation

Mid-Phase II

TNX-1850   COVID-19 Vaccine
Phase I start — targeting 2H 2023

Preclinical

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 1H 2023

Preclinical

Management Team

“Many frontiers remain in the fields of medical science and drug development. At Tonix, we have carefully chosen pursuits in immunology, rare diseases, infectious diseases, and central nervous system disorders. We are building capabilities in synthetic biology, precision medicine, protein engineering, and vaccine manufacturing to develop better and safer medicines. Our ultimate goals are to improve and extend the lives of millions of people and, importantly, to reward the dedication and commitment of our stakeholders.”
— Dr. Seth Lederman, M.D., President and CEO, Tonix Pharmaceuticals

*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.